XAIR
What one share of Beyond Air holds
Surgical and Medical Instruments and Apparatus
We are a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (“NO”) generators and delivery systems (the “LungFit® platform”) capable of generating NO from ambient air. The Company’s first device, LungFit® PH received premarket approval (“PMA”) from the FDA in June 2022.
Beyond Air’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $14.43 |
|---|---|
| Profit | −$62.88 |
| Capex (buildings and equipment) | $1.94 |
| Free cash flow | −$36.79 |
| Cash and investments | $13.20 |
| Debt | $29.82 |
| Book value | $2.69 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | — | −$1,203 | $16.29 | −$490.69 | — | −$549.73 |
| 2018 | — | −$670.66 | $13.74 | −$557.77 | — | $73.56 |
| 2019 | $363.55 | −$308.69 | $2.66 | $60.46 | — | $184.74 |
| 2020 | $48.33 | −$711.44 | $1.52 | −$531.67 | — | $450.71 |
| 2021 | $19.39 | −$508.19 | $19.77 | −$456.07 | — | $558.25 |
| 2022 | — | −$672.85 | $21.51 | −$382.01 | — | $973.08 |
| 2023 | — | −$744.87 | $51.74 | −$492.25 | — | $493.39 |
| 2024 | $13.98 | −$726.68 | $69.30 | −$744.98 | — | $218.28 |
| 2025 | $21.89 | −$275.45 | $34.76 | −$260.54 | — | $65.80 |
| 2026 | $18.50 | −$80.11 | $2.47 | −$46.19 | — | $10.39 |